Second Sight Medical (EYES) Prices 10M Share Offering at $5/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- US stock futures rise on tech rebound before Nvidia, inflation tests
- Oil falls 4% as investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Grand Canyon Education places CFO on leave amid stock trade probe
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Funds sell $44bn in semiconductors on AI concerns
After-Hours Stock Movers 06/22: (SEAC) (SHAK) (CLNE) Higher; (GMTX) (EYES) (BSY) Lower (more...)
June 22, 2021 5:56 PM EDTAfter-Hours Stock Movers:
Gemini Therapeutics, Inc. (Nasdaq: GMTX) 35.7% LOWER; announced initial data from its Phase 2a ReGAtta study of GEM103 as of May 2021 in patients with geographic atrophy (GA) secondary to dry AMD. ReGAtta is a dose escalation trial of GEM103, which is intravitreally administered recombinant human complement factor H (CFH), in dry AMD patients. The trial, which remains ongoing, is designed to evaluate safety and tolerability, as well as measures of intraocular pharmacokinetics (PK) and disease-relevant biomarkers, to inform the late-stage development program.
Second Sight... More
Second Sight Medical (EYES) Announces Proposed Offering, Size not Disclosed
June 22, 2021 4:39 PM EDTSecond Sight Medical Products, Inc. (NASDAQ: EYES) (Second Sight or the Company) a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be... More
